Editor's key points † Phenylephrine is known to reduce cerebral oxygenation. † Fourteen patients received phenylephrine during normocapnia, hypocapnia, and hypercapnia. † Hypocapnia intensified, and hypercapnia blunted, the phenylephrineinduced reduction in cerebral oxygenation. † The study presents important data regarding interaction between CO 2 and phenylephrine and the effects on cerebral oxygenation.
Phenylephrine is one of the most commonly used vasopressors including in patients with acute neurological injury. There are a number of reports that cerebral tissue oxygen saturation (Sct O 2 ) measured using near-infrared spectroscopy (NIRS) is decreased, even though arterial pressure is increased, after phenylephrine bolus and infusion administration in anaesthetized and awake humans. 1 -4 Because cerebrovascular tone is powerfully modulated by carbon dioxide (CO 2 ), we hypothesized that the magnitude of the phenylephrine-induced decrease in Sct O 2 is influenced by arterial blood CO 2 partial pressure (Pa CO 2 ) . During hypercapnia, one may see a reduction in the decrease in Sct O 2 due to hypercapnia-mediated cerebral vasodilation, and during hypocapnia, the opposite effect may occur. Manipulation of Pa CO 2 is common in the operating theatre and intensive care unit. Within this context, a full understanding of how Sct O 2 is affected by phenylephrine administration at different Pa CO 2 levels will facilitate clinical decision making. This will be especially true in patients who are at an increased risk of cerebral ischaemia and hypoxia. In this study, it was our aim to determine whether the phenylephrine-induced decrease in Sct O 2 , measured using frequency domain (FD)-NIRS, is different at distinct Pa CO 2 levels in healthy anaesthetized surgical patients.
Methods
After Institutional Research Board approval, ASA I -II patients undergoing elective non-neurosurgical procedures at University of California Irvine Medical Center were recruited for this study (Table 1) . Both verbal and written informed consents were obtained. Exclusion criteria were: age ≤18 yr old, cerebrovascular disease, symptomatic cardiac disease, symptomatic pulmonary disease, poorly controlled hypertension (systolic arterial pressure ≥140 mm Hg), and poorly controlled diabetes mellitus (blood glucose ≥160 mg dl 21 ) or diabetes mellitus requiring insulin treatment. All patients received nothing by mouth 8 h before surgery.
Measurements
Sct O 2 and total haemoglobin concentration (THC, the sum of oxy-and deoxy-haemoglobin concentrations) were measured by the Oxiplex TS cerebral oximeter (ISS Inc., Champaign, IL, USA), a non-invasive, portable, and quantitative FD-NIRS device. 5 It emits and detects near-infrared light at two differ- ) was determined by the gas analyzer built into the anaesthesia machine (Aisys, GE Healthcare, Madison, WI, USA). Pa CO 2 was analysed using a handheld blood analyzer (iSTAT, Abbott Laboratories, Abbott Park, IL, USA). Arterial blood oxygen saturation was determined by finger pulse oximeter (Sp O 2 ) (LNOP Adt, Masimo Corp., Irvine, CA, USA). The depth of anaesthesia was monitored via the bispectral index (BIS) monitor (S/5 TM M-BIS, GE Healthcare).
Protocol
After induction of anaesthesia with fentanyl (1. 6.7-6.9 kPa (confirmed with Pa CO 2 ). The same protocol used in the normocapnia study was used during both hypocapnia and hypercapnia studies. For any given patient, the same dose of phenylephrine was used at all CO 2 levels. However, the dose of phenylephrine varied (100, 150, or 200 mg) between patients due to inter-individual differences in body weight, response to vasopressor treatment, and extent of anaesthesia-related hypotension. The intervals between phenylephrine boluses were greater than 15 min.
Statistical analysis
Data are presented as mean (SD). Power analysis showed that a sample size of n¼10 would be required (a level 0.05 and statistical power .80%) in order to detect an expected reduction in NIRS-determined Sct O 2 of 3 (3)%. Both one-way analysis of variance (ANOVA) with repeated measurements and the Friedman rank sum test were used to analyse the differences in pre-treatment measurements [E 
Results
Out of 16 patients studied, complete data were obtained in 14 patients [11 males, three females, age 44 (15) yr old, height 175 (10) cm, and weight 80 (14) kg] ( Table 1) . Two patients were not included in analysis due to incomplete Pa CO 2 data secondary to either blood gas analyzer malfunctioning or blood sample mishandling.
Hypocapnia, normocapnia, and hypercapnia were successfully achieved via minute ventilation adjustments as demonstrated by E ′ CO 2 (P,0.0001) and confirmed by Pa CO 2 (P,0.0001; Table 2 ). The pre-treatment measurements of Sct O 2 were significantly different between hypocapnia, normocapnia, and hypercapnia (P,0.0001). The pre-treatment measurements of MAP were also significantly different between different CO 2 levels (P,0.001). However, the pretreatment measurements of CBV, CO, HR, Sp O 2 , and BIS all showed no significant difference between different CO 2 levels (P.0.05).
Phenylephrine treatment induced significant increases in MAP during hypocapnia (P,0.001), normocapnia (P,0.001), and hypercapnia (P,0.01; Table 2 ). Sct O 2 was significantly decreased after phenylephrine treatment during hypocapnia (P,0.001), normocapnia (P,0.001), and hypercapnia (P,0.01). CBV was also significantly decreased during hypocapnia (P,0.01), but not during normocapnia and hypercapnia (P.0.05). Both CO (P,0.001) and HR (P,0.01) were also significantly decreased after phenylephrine treatment at all was significantly increased after phenylephrine administration during hypercapnia (P,0.01) even though the magnitude was small [2 (1) mm Hg], but not during hypocapnia and normocapnia (P.0.05). Changes in both Sp O 2 and BIS were not significant at any CO 2 levels (P.0.05).
Correlation between changes in Sct O 2 and changes in CBV was significant (R 2 ¼0.15, P,0.05) (Fig. 2, pooled data). Phenylephrine-induced changes in both Sct O 2 and CBV were significantly different between hypocapnia, normocapnia, and hypercapnia (P,0.01 and ,0.05, respectively; Fig. 3 and Table 2 ). In contrast, changes in other physiological variables, including MAP, CO, HR, Sp O 2 , and BIS, showed no significant difference between different CO 2 levels (P.0.05).
Discussion
This is the first study to evaluate whether the negative impact of phenylephrine bolus treatment on Sct O 2 is modulated by CO 2 . The results demonstrate that hypocapnia intensifies, while hypercapnia blunts, the phenylephrine-induced decrease in Sct O 2 in propofol -remifentanil-anaesthetized healthy patients. In addition, phenylephrine also causes a significant decrease in CBV during hypocapnia, but not during normocapnia and hypercapnia.
The Sct O 2 -decreasing effect of phenylephrine bolus and infusion administrations has been shown in both anaesthetized and awake humans. 1 -4 Phenylephrine, a pure a 1 -agonist, is one of the most commonly used vasopressors in the perioperative setting. A similar drug, norepinephrine, has also been shown to cause a decrease in Sct O 2 after its infusion administration. 10 How increased arterial pressure, and thus increased perfusion pressure, leads to a decrease in Sct O 2 needs careful consideration. Sct O 2 measures an admixture of arterial and venous blood per unit of cerebral tissue seen by light. 11 12 NIRS measurements show changes when the cerebral arterial to venous blood volume ratio (A:V ratio) changes. A hypothetical mechanism for how A:V ratio is affected by phenylephrine treatment is presented in Figure 4 . We propose that the flow velocity in cerebral arterial bed (mainly arterioles) is increased by a phenylephrineinduced increase in perfusion pressure. At the same time, cerebral blood flow (CBF)-regulating vessels (mainly arterioles) constrict due to stretch or increased transmural pressure-mediated vasoconstriction. In accordance with autoregulation, CBF (velocity multiplied by cross-sectional area) is maintained because the increase in velocity is offset by the decrease in cross-sectional area. Cerebral (9) 35 (9) 22 (4) 35 (7) 35 (9) 0.8 (7) 36 (8) 37 (11) 0.4 (6) vasoconstriction is an indirect autoregulation-mediated consequence, because phenylephrine does not cross the blood-brain barrier and it cannot constrict cerebral vessels directly. 13 A decreased arterial blood contribution secondary to cerebral arteriolar constriction may be partially accountable for the observed decrease in Sct O 2 . The findings that flow velocity measured by transcranial Doppler (TCD) is increased while cerebral oxygenation measured by NIRS is decreased after phenylephrine administration are consistent with the above proposed mechanism. 4 However, caution is needed here because it has been shown that the TCD-measured flow velocity is either slightly decreased or maintained during norepinephrine infusion, another vasopressor with some comparable features to phenylephrine. 10 14 Ito and colleagues' study using positron emission tomography demonstrated that changes in CBV during hypocapnia and hypercapnia are caused by changes in arterial blood volume without changing venous and capillary blood volume. 15 This observation, even though it was based on Pa CO 2 manipulation and not vasopressor administration, supports our speculation that a decreased A:V ratio may have occurred during cerebral vasoconstriction. The significant correlation between changes in CBV and Sct O 2 in this study also suggests a possible cause-effect relationship between changes in cerebral A:V ratio and changes in Sct O 2 measured by NIRS. The above hypothetical explanation based on autoregulatory vasoconstriction is also supported by the CO 2 's modulating effect demonstrated by this study. Specifically, the worsening decrease in Sct O 2 during hypocapnia may merely reflect a more robust autoregulatory mechanism because it has been shown that an impaired autoregulation can be restored by hypocapnia. 16 Nonetheless, the mechanism of how phenylephrine induces cerebral vasoconstriction is complicated. The recent finding that sympathetic nerve activity (SNA) from the superior cervical ganglion is increased after pharmacologically (including phenylephrine) induced rapid and large increase in arterial pressure suggests a role of SNA in cerebral circulation regulation. 17 18 Increased SNA to the brain leads to cerebral vasoconstriction and prevents abrupt cerebral over-perfusion and haemorrhage. 17 18 The biophysical change induced by this SNA mechanism is similar to the above proposed autoregulatory mechanism. The results of this study agree with our previous findings in that both CO and Sct O 2 are consistently decreased after phenylephrine treatment. 1 These concordant changes imply that the decrease in CO is likely to account for the decrease in Sct O 2 . This is further supported by the observation that CBF estimated using transcranial Doppler is decreased when CO, but not MAP, is decreased via lower body negative pressure. The difference between FD-NIRS, the technology adopted by this study, and continuous wave (CW)-NIRS, the technology currently adopted by clinical practice has been described. In brief, FD-NIRS is regarded as a quantitative approach because it has the ability to differentiate between photon absorption and scattering while CW-NIRS is only regarded as a trend monitor due to its inability to differentiate between the two optical properties. Nonetheless, both technologies are similar in that they are not appreciably affected by the extracerebral tissue layers, if the spacing between optodes is optimized. 6 7 20 21 For example, selective clamping of the external carotid artery in a patient with a defective Circle of Willis shows that FD-NIRS measurements are not affected during external carotid artery occlusion (Fig. 5A) . Conversely, in the same patient, clamping of the internal carotid artery shows that pronounced changes in NIRS measurements occur (Fig. 5B) . Clearly, the quantitative FD-NIRS result is both spatially and temporally responsive to changes in cerebral perfusion and oxygenation. Even though phenylephrine causes a consistent decrease in Sct O 2 , the magnitude of the decrease is very small ( 1.5-3.5% absolute change depending on CO 2 level) and seems unlikely to be clinically significant. Al-Rawi and colleagues found that a relative 13% decrease from baseline, which is approximately twice as great as that seen here, correlates with cerebral ischaemia in patients undergoing carotid artery procedures. 22 Importantly, the decrease in Sct O 2 may reflect, at least partially, a decreased arterial blood contribution to NIRS measurements due to cerebral vasoconstriction. Therefore, the phenylephrine-induced decrease in Sct O 2 may not represent real or significant cerebral ischaemia and hypoxia if it is partially attributed to a functional pressure autoregulation mechanism. Caution is needed in extrapolating our results to clinical situations where autoregulation may be impaired. Caution is also needed when interpreting the CBV result because its changes are rather small and the study may be underpowered in detecting the small change. Propofol and remifentanil were used in this study to maintain general anaesthesia because they preserve cerebral autoregulation, 23 cerebrovascular CO 2 reactivity, 24 and CBF -cerebral metabolic rate of oxygen (CMRO 2 ) coupling 25 and they do not possess an intrinsic cerebral vasodilating effect, which may occur with inhalation anaesthetic agents. 26 In summary, this study demonstrates that a phenylephrine bolus results in a consistent but small decrease in Sct O 2 and CBV, and this decrease is intensified by hypocapnia and blunted by hypercapnia. The decrease in CO may not be solely responsible for the decrease in Sct O 2 . A decreased A:V ratio secondary to cerebral vasoconstriction may also account for the phenylephrine-induced decrease in Sct O 2 . The effect of phenylephrine treatment on Sct O 2 and CBV in individuals with injured nervous systems or receiving drugs that abolish autoregulation is not known.
